LGALS9B

Across TCGA pan-cancer cohorts, LGALS9B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LGALS9B data layer compared with 28 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher LGALS9B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS9B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, UCEC, and LIHC are the cancer types where LGALS9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.078	0.594	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.392	0.691	.036	3	view →
SKCM	DFS	Median	II,III,IV	0.862	0.250	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LGALS9B–BLCA (DFS)

Open the BLCA breakdown →